Mono Pharmacare operates in the pharmaceutical industry, primarily focused on marketing pharmaceutical products and serving as a distributor for various pharmaceutical companies. The company collaborates with contract manufacturers who produce pharmaceutical products according to the compositions specified by Mono Pharmacare. These products are then sold under the brand name "DLS Export".
| Bidding Dates |
|---|
| 28 Aug 2023 - 30 Aug 2023 |
| Subscription |
|---|
| 12.77x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹1,12,000 | 1 | 1 | 4000 | 5.3 M | ₹26 - ₹28 | 70 % | ₹137.8 M - ₹148.4 M | RHP DOC |
Mono Pharmacare IPO SUBSCRIPTION STATUS
30 Aug '23Mono Pharmacare IPO overall subscription rate was 12.77 times the total available shares
Mono Pharmacare IPO retail subscription rate was 18.4 times in the retail segment
Mono Pharmacare IPO non-institutional investor subscription rate was 7.69 times in the non-institutional investor category
Mono Pharmacare IPO Qualified Institutional Bidder subscription rate was 10.27 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 45% | 45% | 10% |
30 Aug 2023 (Day 3) | 18.4x | 7.69x | 10.27x |
29 Aug 2023 (Day 2) | 7.74x | 0.82x | 0.04x |
28 Aug 2023 (Day 1) | 3.09x | 0.29x | 0x |
Mono Pharmacare FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from Operations (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) | Margins |
| FY23 | 12.3 | 584.8 | -389.5 | -395.8 | 5.1% |
| FY22 | 3.5 | 369.8 | 2.4 | 2.3 | 3.5% |
| FY21 | 1.0 | 282.7 | -7.8 | -8.5 | 3.0% |
Mono Pharmacare IPO SUBSCRIPTION STATUS DETAILS
Mono Pharmacare had 5.3 M shares on offer
Mono Pharmacare IPO offer price was in the range ₹26 - ₹28
Mono Pharmacare IPO minimum Investment was ₹112000
Mono Pharmacare IPO issue size was ₹ 137.8 M - ₹ 148.4 M
Mono Pharmacare had a minimum lot size of 4000 Shares per application
Mono Pharmacare NUMBER OF SHARES ON OFFER
Mono Pharmacare IPO IMPORTANT DATES
| Issue Open Date | 28 Aug 2023 |
| Issue close Date | 30 Aug 2023 |
| Allotment Date | 04 Sep 2023 |
| Refund Date | 05 Sep 2023 |
| Demat Account Credit Date | 06 Sep 2023 |
| Listing Date | 07 Sep 2023 |
| Listing on Exchange(s) | NSE |
| Mono Pharmacare Allotment Status | Exchange |
Mono Pharmacare IPO subscription opened on 28 Aug 2023, and closed on 30 Aug 2023
IPO allotment for Mono Pharmacare was finalized on Monday, 04 Sep 2023
IPO listing for Mono Pharmacare was on NSE on Thursday, 07 Sep 2023
Mono Pharmacare IPO LISTING GAINS
| Issue Price (adjusted) | 28.0 |
| Listing Open Price | 29.0 |
| Listing Close Price | 30.4 |
| Listing Gain% | 3.6% |
| Current Gain% | -72.9% |
Mono Pharmacare Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mono Pharmacare Ltd. | 7.6 | 13.4 | 38.1 | -0.4 | 0.1 | 1.1 | 0.3 | 165.7 | -2.1 | 0.4 | -88.6 | 0.2 | -88.6 |
| Sun Pharmaceutical Industries Ltd. | 1948.8 | 467582.4 | 38.7 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8312 | 220657.5 | 75.4 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4932.5 | 187616.5 | 86 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1472.7 | 118972.5 | 35.3 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1123.4 | 113040.3 | 22.4 | 2.3 | 4.2 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Mono Pharmacare INFORMATION ON IPO ISSUE
About Mono Pharmacare
Mono Pharmacare operates in the pharmaceutical industry, primarily focused on marketing pharmaceutical products and serving as a distributor for various pharmaceutical companies. The company collaborates with contract manufacturers who produce pharmaceutical products according to the compositions specified by Mono Pharmacare. These products are then sold under the brand name "DLS Export".
Object of the Issue
- To meet the working capital requirements
- General corporate purposes
- To meet the issue expenses
Mono Pharmacare - PROMOTERS
| Name |
|---|
| Panilam Lakhatariya |
| Supal Lakhatariya |
Mono Pharmacare Lead Manager to the Issue
Unistone Capital Private Limited
mb@unistonecapital.com
Mono Pharmacare Registrar to the issue
Bigshare Services Private Limited
ipo@bigshareonline.com
Mono Pharmacare Strengths
Wide product offerings
Mono Pharmacare boasts a diverse product portfolio that encompasses various categories, including antibiotics, antifungal medications, anti-cough, cold, and anti-allergic remedies, antacids and antiemetics, analgesics and antipyretics (pain and fever relief), nutraceuticals (nutrition-based products), skincare solutions, antiseptics, cardiac medications, diabetic treatments, and cosmetic products
Business model
Mono Pharmacare employs a scalable and asset-light business model, enhancing competitiveness with a diverse range of pharmaceutical products
Experienced team
The company boasts an experienced management team and promoters with a proven track record and industry expertise
Mono Pharmacare Risks
High-volume, low-margin business
The company operates in a high-volume, low-margin business. Any interruption in turnover or failure to consistently increase it could significantly impact the business, financial condition, and operational results
Dependent on few customers
A significant portion of the company's revenue comes from its top ten customers. The potential loss of business from any of these key clients could negatively impact both the company's revenue and profitability
Legal proceedings
The company is currently engaged in certain legal proceedings that, if decided unfavorably, could have implications for its business operations and financial condition
IPO FAQs
The promoters of the company are Panilam Lakhatariya and Supal Lakhatariya.
The category allocation of qualified institutional buyers is 10.0%, the category allocation of non individual investors or high networth individuals is 45.0% and for retail investors it is 45.0%.
The price band of the IPO is Rs 26.0 - 28.0.
The IPO application opens on Aug 28, 2023 and closes on Aug 30, 2023.
The minimum lot size for the IPO is 4000. The maximum lot size for the IPO is 4000.
For all category investors, the minimum application amount for this IPO is Rs. 112,000.0, the maximum value for this IPO is Rs 112,000.0.
This IPO will be allotted on Sep 04, 2023.
The refund will be credited to your account on Sep 05, 2023.
The allotted shares will be credited to your demat on Sep 06, 2023.
Mono Pharmacare Ltd.’s shares listed on the stock exchanges on Sep 07, 2023.